B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

ADORA2B

MOLECULAR TARGET

adenosine A2b receptor

UniProt: P29275NCBI Gene: 13624 compounds

ADORA2B (adenosine A2b receptor) is targeted by 24 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ADORA2B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1neca4.86128
213 dipropyl 8 cyclopentylxanthine dpcpx4.5796
3n6 cyclopentyladenosine4.2871
4ib meca4.0154
5zm 2413853.8747
6pentoxifylline3.5634
7istradefylline3.5032
8cgs 159433.4731
9sch 582613.4029
10xanthine amine congener3.3728
118 phenyl theophylline3.2625
12mivebresib3.0019
13enprofylline2.9418
14methylthioadenosine2.9418
15psilocin2.7715
16rolofylline2.7114
172-Chloroadenosine 2-Chloroadenosine.2.6413
18aristeromycin2.6413
19Adenosine2.087
20tozadenant2.087
21ciforadenant1.956
22Caffeine1.795
23rs mefloquine1.795
24st15351.795

About ADORA2B as a Drug Target

ADORA2B (adenosine A2b receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 24 compounds with documented ADORA2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ADORA2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.